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Abstract
Purpose The ∼15 kDa variable domains of camelid heavy-
chain-only antibodies (called Nanobodies®) have the
flexibility to be formatted as monovalent, monospecific,
multivalent or multispecific single chain proteins with
either fast or slow pharmacokinetics. We report the
evaluation of the fast kinetic anti-epidermal growth factor
receptor (EGFR) Nanobody 7D12, labelled with
68Ga via
the novel bifunctional chelate (BFC) p-isothiocyanatoben-
zyl-desferrioxamine (Df-Bz-NCS). Df-Bz-NCS has recently
been introduced as the chelate of choice for
89Zr immuno-
positron emission tomography (PET).
Methods Nanobody 7D12 was premodified with Df-Bz-NCS
at pH 9. Radiolabelling with purified
68Ga was performed at
pH 5.0–6.5 for 5 min at room temperature. For in vitro
stability measurements in storage buffer (0.25 M NaOAc with
5m gm l
−1 gentisic acid, pH 5.5) at 4°C or in human serum at
37°C, a mixture of
67Ga and
68Ga was used. Biodistribution
and immuno-PET studies of
68Ga-Df-Bz-NCS-7D12 were
performed in nude mice bearing A431 xenografts using
89Zr-
Df-Bz-NCS-7D12 as the reference conjugate.
Results The Df-Bz-NCS chelate was conjugated to Nano-
body 7D12 with a chelate to Nanobody molar substitution
ratio of 0.2:1. The overall
68Ga radiochemical yield was
55–70% (not corrected for decay); specific activity was
100–500 MBq/mg. Radiochemical purity of the conjugate
was >96%, while the integrity and immunoreactivity were
preserved.
68/67Ga-Df-Bz-NCS-7D12 was stable in storage
buffer as well as in human serum during a 5-h incubation
period (<2% radioactivity loss). In biodistribution studies
the
68Ga-labelled Nanobody 7D12 showed high uptake in
A431 tumours (ranging from 6.1±1.3 to 7.2±1.5%ID/g at
1–3 h after injection) and high tumour to blood ratios,
which increased from 8.2 to 14.4 and 25.7 at 1, 2 and 3 h
after injection, respectively. High uptake was also observed
in the kidneys. Biodistribution was similar to that of the
reference conjugate
89Zr-Df-Bz-NCS-7D12. Tumours were
clearly visualized in a PET imaging study.
Conclusion Via a rapid procedure under mild conditions a
68Ga-Nanobody was obtained that exhibited high tumour
uptake and tumour to normal tissue ratios in nude mice
bearing A431 xenografts. Fast kinetic
68Ga-Nanobody
conjugates can be promising tools for tumour detection
and imaging of target expression.
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The epidermal growth factor receptor (EGFR, HER1,
ERb1) is a transmembrane protein of the tyrosine kinase
receptor family. Activation of EGFR causes signalling
that may lead to cell division, increased motility,
angiogenesis and suppression of apoptosis [1]. EGFR
over-expression or constitutive activation has been shown
to be associated with poor survival and recurrences in
many human malignancies [2]. Detection of EGFR
expression via nuclear medicine visualization may provide
advantages over immunohistochemical staining of tumour
biopsies, since evaluation of both the primary tumour as
well as the metastases can be achieved. In addition, such
confirmation of EGFR expression can be of value as a
scouting procedure to select patients for anti-EGFR
therapy with approved monoclonal antibodies (mAbs) like
cetuximab or panitumumab or small molecular tyrosine
kinase inhibitors. On this latter topic several studies with
intact anti-EGFR (αE G F R )m A b so rm A bf r a g m e n t s
labelled with single photon emission computed tomogra-
phy (SPECT) (
111In,
99mT c )o rp o s i t r o ne m i s s i o nt o m o g -
raphy (PET) (
64Cu,
89Zr) radionuclides have been reported
[3–9].
Nanobody technology provides new perspectives for
mono- as well as multitarget tumour detection and
therapy [10–12]. Nanobodies are derived from a unique
antibody format that is present in species from the family
of Camelidae, including llama, camel and dromedary.
These animals contain, besides their conventional anti-
body repertoire, an antibody class consisting of heavy
chains only [10, 13]. The variable region of the heavy-
chain-only antibodies (VHH) represents the complete
binding unit of the antibody. Because of the small size of
these VHH fragments (∼15 kDa), this binding unit is also
called Nanobody®. Although being smaller than a scFv
fragment, a Nanobody has full antigen-binding potential
and does not show aggregation problems, because of
hydrophilic instead of hydrophobic patches in the VH and
VL domains. Due to their single domain character,
standard molecular biology techniques such as polymerase
chain reaction (PCR) allow for the facile purification and
selection of appropriate Nanobody candidates from the full
antibody repertoire of immunized animals [14]. Unique
features of the Nanobody technology platform in compar-
ison to conventional mAb technology are easy and rapid
drug development, and the easy and cheap production in
bacteria and yeast [10, 15].
For a proof of concept we used the Nanobody
technology platform to construct two αEGFR Nanobodies
[11]. The biodistribution of a
177Lu-labelled bivalent
αEGFR Nanobody (αEGFR-αEGFR) in A431 tumour-
bearing nude mice showed a tumour uptake of 5.0±1.4
percentage of the injected dose per gram of tissue (%ID/
g) at 6 h after injection and high tumour to normal tissue
ratios (e.g. tumour to blood ratio >80) due to rapid blood
clearance. Simple fusion of an anti-albumin Nanobody
building block gave a 50-kDa single-chain construct
(αEGFR-αEGFR-αAlb) that showed pharmacokinetics
and tumour uptake (up to 35.2±7.5%ID/g) comparable
to cetuximab, but faster and deeper tumour penetration.
Therefore, such Nanobody formats might be ideal for
imaging and therapeutic purposes, respectively.
In the present study we evaluated the in vivo diagnostic
potential of fast kinetic αEGFR Nanobody 7D12 with the
immuno-PET approach. For this purpose the short-lived
positron emitter
68Ga (T½=68 min, Eβ+max 1.92 MeV) was
chosen.
68Ga is an attractive positron-emitting radionuclide
since it is cyclotron-independently available via the
68Ge/
68Ga generator system.
In aqueous solutions the three-valent gallium forms a
complex with many bifunctional chelates (BFCs) con-
taining oxygen and nitrogen as donor atoms. The only
clinically used BFC for
68Ga is 1,4,7,10-tetraazacyclodo-
decane-N,N′,N″,N′″-tetraacetic acid (DOTA), but fast
complex formation requires a high temperature [16–19].
More recently, several new chelates have been described
for labelling of
68Ga to heat-labile proteins at ambient
temperature including 1,4,7-triazacyclononane-1,4-7-tria-
cetic acid (NOTA) and N,N′-bis[2-hydroxy-5-(carbox-
yethyl)benzyl]ethylenediamine-N,N′-diacetic acid
(HBED-CC) [19–21]. However, this new generation of
BFCs is not yet available for clinical immuno-PET
applications.
For coupling of the long-lived positron emitter
89Zr
(T½=78.4 h, Eβ+max 0.9 MeV) (23%) to intact mAbs, we
recently introduced the novel BFC p-isothiocyanatobenzyl
derivative of desferrioxamine B (Df-Bz-NCS) [22, 23].
The choice of desferrioxamine B is attractive because it
has been used safely in the clinical setting for many years.
Since the hydroxamate function in desferrioxamine B has
also been used for coupling of
67Ga in the past [24–27],
we investigated whether this same Df-Bz-NCS can be
used for labelling of
68Ga under mild conditions. If so, a
similar kind of GMP-compliant radiochemistry can be
used for labelling of slow kinetic mAbs with
89Zr, and fast
kinetic mAb fragments with
68Ga.
In this study, after establishing optimal
68Ga labelling
procedures by using a control intact IgG mAb, the
bifunctional chelate Df-Bz-NCS was conjugated to αEGFR
Nanobody 7D12 and subsequently radiolabelled with
68Ga.
The resulting
68Ga-Df-Bz-NCS-7D12 conjugate was ana-
lysed for stability at 4°C in storage buffer and at 37°C in
serum, whereas its in vivo behaviour was investigated via
biodistribution and animal PET studies, using
89Zr-Df-Bz-
NCS-7D12 as the reference.
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Materials
All reagents were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless otherwise stated. Deionized
water (18 MΩ*cm) and ultra pure HCl (Ga content 0.02
ng
natGa/g) was used. No other special measures were
taken regarding working under strict metal-free conditions.
Df-Bz-NCS was purchased from Macrocyclics (Dallas,
TX, USA, catalog No. B-705). Nanobody 7D12 was
generated by Ablynx NV (Ghent, Belgium) as described
previously [14] and kindly provided to us. The selection,
production and characterization of chimeric mAb U36
( c m A bU 3 61 1 . 5 3m g / m l )d i r e c t e da g a i n s tC D 4 4 v 6h a s
been described elsewhere [28]. The human epidermoid
cervical carcinoma cell line A431 was obtained from the
American Type Culture Collection (www.atcc.com),
ATCC number: CRL-1555. The head and neck squamous
cell carcinoma (HNSCC) cell line UM-SCC-11B was
o b t a i n e df r o mD r .T . E .C a r e y( A n nA r b o r ,M I ,U S A )
[29].
68Ga was obtained from a commercial
68Ge/
68Ga
generator based on a TiO2 bedding with 1.85 GBq
68Ge-
loaded activity (IGG100; Eckert & Ziegler, Berlin,
Germany).
67Ga was purchased as
67Ga-citrate (74 MBq/
ml) from Covidien (Mansfield, MA, USA). [
89Zr]Zr-
oxalate in 1.0 M oxalic acid (≥ 0.15 GBq/nmol) was from
IBA Molecular (www.iba.be/molecular).
Purification and concentration of
68Ga and
67Ga
The
68Ga was eluted from the
68Ge/
68Ga generator as
described by Velikyan et al. [16]. In short, the generator
was eluted according to the manufacturer’sp r o t o c o lw i t h
3.5 ml ultra pure 0.1 M HCl solution. To that solution
3.5 ml ultra pure 8 M HCl was added under stirring, to
give a final concentration of ∼ 4 M HCl. The solution was
passed through a pre-treated (1 ml 100% ethanol, 1 ml
deionized water, 1 ml 4 M HCl) anion exchange column
[Chromafix, PS-HCO3 (s), Macherey-Nagel, Düren,
Germany], the column was washed with 2 ml of 4 M
HCl, flushed with air, and then the
68Ga was eluted from
the Chromafix column with 200 μl deionized water
(elution efficiency >85%). The use of ultra pure HCl
implies that this procedure attributes at most 1.1 pmol
natGa to this eluate.
67GaCl3 was obtained from
67Ga-citrate. To this end,
67Ga-citrate was mixed with an equal volume of ultra
pure 8 M HCl. This solution was passed through a pre-
treated Chromafix column and eluted as described for
68Ga.
In all preparations for in vitro evaluation
68/67Ga was
used, while for in vivo evaluation only
68Ga was applied.
Preparation of
68/67Ga-Df-Bz-NCS-cmAb U36
For development of labelling procedures, the 150-kDa
intact cmAb U36 was used as the control mAb. cmAb
U36 was premodified with Df-Bz-NCS as described by
Perk et al. [22] (Fig. 1). In short, 5 mg cmAb U36 (33
nmol) reacted with 20 μl Df-Bz-NCS (100 nmol) in
dimethyl sulphoxide (DMSO) for 30 min at 37°C at pH 9
in a shaker, in a total volume of 1 ml. Nonconjugated
chelate was removed by size exclusion chromatography
using a PD-10 column (GE Healthcare Life Science) with
0.25 M NaOAc pH 5.5 as eluant. The flow through and the
first 1.5 ml were discarded. The next 2 ml containing the
premodified mAb were stored.
Ga-Df complex chelate formation conditions were
selected by varying pH and protein concentration. As a
result, the following procedure was developed; to 10–
200 μl( =a)
68Ga and/or
67Ga in deionized water (3× a μl),
3MN H 4OAc buffer pH 7.2 were added and mixed for
5 min at room temperature. Subsequently the premodified
cmAb U36 (100–1,000 μg) in 0.25 M NaOAc pH5.5 was
added; the final reaction volume was 2 ml. The reaction
was stopped after 5 min at room temperature by the
addition of 50 μl 50 mM ethylenediaminetetraacetate acid
(EDTA), followed by PD-10 column purification using 0.25
M NaOAc with 5 mg ml
−1 gentisic acid, pH 5.5, as eluant.
The flow through and the first 1 ml were discarded. The
next 2 ml containing the
68/67Ga-labelled cmAb U36 was
collected and used for further experiments.
Preparation of
68/67Ga-Df-Bz-NCS-7D12
The same protocol was applied for the modification and
radiolabelling of the αEGFR Nanobody 7D12. In short,
2 mg 7D12 (125 nmol) was conjugated with 375 nmol Df-
Bz-NCS and after PD-10 column purification the premodi-
fied 7D12 (200–1,000 μg) was labelled with
68/67Ga as
described for cmAb U36.
Preparation of
89Zr-Df-Bz-NCS-7D12
The 7D12 nanobody was premodified as described above
with a threefold molar excess of Df-Bz-NCS chelate. After
PD-10 column purification the premodified 7D12 was
labelled with
89Zr as described by Perk et al. [22]. In short,
Df-Bz-NCS-7D12 (100–1,000 μg) was labelled with
89Zr
(37 MBq) in 0.25 M HEPES buffer pH 7.0 at room
temperature in a total volume of 2 ml. The
89Zr-Df-Bz-
NCS-7D12 was purified by PD-10 column using 0.25 M
NaOAc with 5 mg ml
−1 gentisic acid, pH 5.5, as eluant.
After discarding the flow through and the first 1 ml, the
next 2 ml containing the
89Zr-labelled 7D12 was collected
for further experiments.
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The Df-Bz-NCS to 7D12 molar ratio was determined
following a general method using a known nanomolar
excess of GaCl3 spiked with
67Ga. In short, 250 nmol
GaCl3 (in 4 M ultra pure HCl) was mixed with ∼37 MBq
67Ga and purified according to the aforementioned method
using the anion Chromafix column. Thereafter, 500 μgo f
premodified Df-Bz-NCS-7D12 was labelled according to
the developed protocol with 20–60 nmol of the above
prepared
67Ga-GaCl3, and the Df to 7D12 molar ratio was
calculated. For comparison the Df to 7D12 molar ratio was
also determined with the use of zirconium oxalate spiked
with
89Zr.
Analysis
68Ga was measured using Eγ=511 KeVand
67Ga with Eγ=
185 KeV. When dual isotope labelling products were
produced,
67Ga radioactivity measurements were performed
at least 20 h after production (after decay of
68Ga). Each
68/
67Ga-labelled product was analysed by instant thin-layer
chromatography (ITLC) to determine the radiochemical
labelling efficiency and radiochemical purity. The integrity
of the Nanobody and mAb was analysed by high-
performance liquid chromatography (HPLC) and sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) followed by phosphor imaging (Storm 820, GE
Healthcare). Immunoreactivity was determined by a cell-
Fig. 1 Two-step synthesis of
68Ga-Df-Bz-NCS-mAb with
the bifunctional chelate
Df-Bz-NCS
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analysis of the
68/67Ga-labelled products was performed on
chromatography strips (Biodex, Shirley, NY, USA); 2 μl
was spotted on an ITLC strip with 50 mM EDTA in Milli-Q
as mobile phase. HPLC analysis was performed on a Jasco
HPLC system using a Superdex™ peptide size exclusion
column (GE Healthcare Life Sciences) when a labelled
Nanobody was injected, or a Superdex™ 200 10/300 GL
size exclusion column when labelled cmAb U36 was
injected, with a mixture of 0.05 M sodium phosphate and
0.15 M sodium chloride (pH 6.8) as eluant at flow rates of
1.0 and 0.5 ml min
−1, respectively. Gel electrophoresis was
performed on a PhastGel System (GE Healthcare Life
Sciences) using high-density SDS-PAGE gels when a
labelled Nanobody was applied or 7.5% SDS-PAGE gels
when labelled U36 was applied, under non-reducing
conditions. Immunoreactivity was determined by measuring
the binding of the
68/67Ga-7D12 or
68/67Ga-cmAb U36 to a
serial dilution of 2% paraformaldehyde fixed A431 cells or
0.2% glutaraldehyde fixed 11B cells, respectively, essen-
tially as described by Lindmo et al. [30].
In vitro stability
To determine the in vitro stability of the gallium-labelled
Nanobodies, 500 μg
68/67Ga-labelled 7D12 product was
stored at 4°C up to 24 h in 0.25 M NaOAc pH 5.5,
containing 5 mg ml
−1 gentisic acid as antioxidant and
compared with
89Zr-7D12. Amounts of activity at the start
of storage were 120 MBq of
68Ga, 20 MBq of
67Ga and 20
MBq of
89Zr. After 5 and 24 h storage aliquots were taken
and analysed by ITLC, HPLC and SDS-PAGE.
Stability of
68/67Ga-labelled 7D12 was also tested in
freshly prepared human serum and compared with
89Zr-
7D12. Activity amounts at the start of storage were 80 MBq
68Ga, 18 MBq
67Ga and 18 MBq
89Zr. The labelled 7D12
(300 μg) was incubated at 37°C in a CO2-enriched
atmosphere (5% CO2) with freshly prepared human serum
(1:4) in the presence of 0.02% NaN3. Aliquots were taken
after 5 and 24 h storage and analysed by ITLC and HPLC.
Biodistribution study
The distribution of
68Ga-Df-Bz-NCS-7D12 was examined
using nude mice (Hsd:Athymic Nude-Foxn1
nu,2 0 –30 g,
Harlan Laboratories, Horst, the Netherlands) bearing
subcutaneously implanted human xenografts of the vulvar
tumour cell line A431 at two lateral sides. All animal
experiments were done according to NIH Principles of
Laboratory Animal Care and Dutch national law (Wet op de
dierproeven, Stb 1985, 336).
In this experiment mice bearing A431 xenografts were
injected with 0.35 MBq
68Ga-Df-Bz-NCS-7D12 (6 μg)
via the retro-orbital plexus. As reference compound,
0.35 MBq
89Zr-Df-Bz-NCS-7D12 (6 μg) was used.
Unlabelled 7D12 was added to the injection mixture to
obtain a final dose of 50 μgp e rm o u s e .A t1 ,2a n d3h
post-injection (p.i.) four mice were anaesthetized, bled,
killed and dissected. Blood, tumour and normal tissues
were weighed and radioactivity was measured in a gamma
counter (Wallac, Turku, Finland). Radioactivity uptake for
each sample was calculated as %ID/g.
PET study
PET imaging was performed on a HRRT PET scanner
(Siemens/CTI [31]), a dedicated human brain scanner.
Three A431 xenograft-bearing mice were anaesthetized by
inhalation of 2% isoflurane, injected with 5 MBq
68Ga-Df-
Bz-NCS-7D12 (85 μg) via the retro-orbital plexus and
scanned for 3 h. In addition, three mice were injected with
2.5 MBq
89Zr-Df-Bz-NCS-7D12 (85 μg). Unlabelled 7D12
was added to the injection mixture to obtain a final dose of
100 μg per mouse. Transmission scans for attenuation and
scatter correction were routinely obtained with each
emission scan. Three-dimensional emission scans were
acquired in list mode during 180 min. A single frame static
image was reconstructed using ordinary Poisson ordered
subsets expectation maximization (OP-OSEM). For visual-
ization of the images, the freely available Amide’sA
Medical Imaging Data Examiner (AMIDE) program was
used [32].
Statistical analysis
Differences in tissue uptake between injected conjugates
were statistically analysed for each different time point with
SPSS 15.0 software using Student’s t test for unpaired data.
Two-sided significance levels were calculated and p <0.01
was considered statistically significant.
Results
Preparation of
68/67Ga-Df-Bz-NCS-cmAb U36
The Ga-Df formation conditions were investigated by
performing experiments with premodified Df-Bz-NCS-
cmAb U36. The Df-Bz-NCS chelate was coupled at pH 9
to the lysine groups in a threefold molar excess via a 30-
min incubation at 37°C.
When labelling was performed for 5 min in a 2 ml
acetate solution at a pH in the range of 5.0–6.5 and an
activity level of 200 MBq
68Ga (2 pmol) and 37 MBq
67Ga
(25 pmol), the labelling yield was consistently >90%
provided the amount of mAb was >200 μg (measured up
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(i.e. 0.35 nmol bound Df-groups) a labelling yield of 80%
was obtained. When using a naked cmAb U36 under these
conditions, < 1% of Ga was co-eluted with the PD-10
protein fraction.
After PD-10 purification the labelled cmAb U36 was
stored in 2 ml 0.25 M NaOAc with 5 mg ml
−1 gentisic acid,
pH 5.5, and analysed. The radiochemical purity was always
96–99%, as determined with ITLC and HPLC. The
immunoreactive fraction was determined by an overnight
immunoreactivity assay (when using
67Ga) and was 81–
86%. The integrity of the labelled cmAb U36 was optimal
as determined with SDS-PAGE and HPLC analysis (data
not shown). The radiation dose derived from labelling with
200 MBq
68Ga and its subsequent full decay did not affect
the integrity and immunoreactivity of the
68/67Ga product,
which means that our chosen 0.25 M NaOAc with
5m gm l
−1 gentisic acid, pH 5.5 buffer protected adequately
against radiation damage. Dilution of the
68/67Ga-cmAb
U36 product with human serum to a solution containing 70
pmol/ml Df showed <1% loss of label. Upon storage of this
solution at 37°C, the radiochemical purity of cmAb U36
decreased during 5 h an additional 2% and during 24 h an
additional 10%, as determined by ITLC and confirmed with
HPLC.
Preparation of
68/67Ga-Df-Bz-NCS-7D12
and
89Zr-Df-Bz-NCS-7D12
The aforementioned conditions applied to Nanobody 7D12
gave 0.2 desferal groups per Nanobody molecule. Labelling
(200–1,000 μg) of the Df-Bz-NCS-7D12 with
68/67Ga
resulted in overall radioactivity yields of 55–70% (not
corrected for decay). Radiochemical purity was always 96–
99%, as determined by HPLC and ITLC. Immunoreactivity
was 40–60% for the 3-h incubation assay at 37°C while the
overnight assay at 4°C using
67Ga showed 80–85%. The
integrity of the Nanobody was preserved as determined
with SDS-PAGE and HPLC analysis (see Fig. 2).
For the
89Zr-Df-Bz-NCS-7D12 the overall radioactivity
yield was 59–73%, radiochemical purity was always 97–
99% and the immunoreactivity was 80–85% (determined
with the overnight assay at 4°C).
In vitro stability
In vitro stability of
68/67Ga-Df-Bz-NCS-7D12 was com-
pared with
89Zr-Df-Bz-NCS-7D12. Radiochemical purity of
68/67Ga-Df-Bz-NCS-7D12 was 98±1% at the start and only
slightly decreased during 5 h incubation in buffer at 4°C
(1.5−2.0% release of
68/67Ga); after 24 h the decrease was
6–7% as determined with ITLC and confirmed with HPLC.
For
89Zr-Df-Bz-NCS-7D12 the radiochemical purity was
also 98±1% at the start, which decreased to 97±1% after
24 h at 4°C. The integrity of both labelled 7D12 Nano-
bodies was not affected after 24 h at 4°C, as determined
with SDS-PAGE and HPLC.
In human serum at 37°C, radiochemical purity of both
labelled 7D12 Nanobodies slightly decreased during 5 h in
human serum (1–2% release for both compounds), and after
24 h the percentage of
68/67Ga that was dissociated was 7–
8% and 1–2% for
89Zr as determined by ITLC and
confirmed with HPLC.
Biodistribution study
For the biodistribution study nude mice bearing A431
xenografts were injected with either 0.35±0.05 MBq
68Ga-
Df-Bz-NCS-7D12 or 0.35±0.01 MBq
89Zr-Df-Bz-NCS-
7D12 as the control group (Fig. 3). After 1 h high uptake
was seen in tumour tissue for both radioisotopes (6.1±1.3%
ID/g for
68Ga and 7.5±1.9%ID/g for
89Zr), a level which
remained constant up to 3 h p.i. (6.1±0.9 and 7.6±1.9%ID/
g at 2 h, and 7.2±1.5 and 7.4±1.6%ID/g at 3 h p.i. for
68Ga
and
89Zr, respectively). High radioactivity uptake was
found in the kidneys, urine and bladder. Except for some
liver uptake (2.1±0.1 and 0.7±0.1%ID/g at 1 h p.i. for
68Ga
and
89Zr, respectively) all other organs showed low uptake
Fig. 2 SDS-PAGE followed by
phosphor imaging analysis (a)
and HPLC chromatogram (b)o f
purified
68Ga-Df-Bz-NCS-
7D12, where the upper panel
represents the UV profile at 280
nm and the lower panel the
radioactivity profile
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68Ga and<0.3±0.1%
ID/g for
89Zr). For both radioisotopes tumour to blood
ratios increased at later time points. At 1 h the tumour to
blood ratio for
68Ga was 8.2 and increased to 14.4 at 2 h
and 25.7 at 3 h p.i., while the tumour to blood ratios for
89Zr were 14.8, 35.2 and 42.4 at 1, 2 and 3 h, respectively.
In general, the overall biodistribution of both radioisotopes
was very similar. For all time points significant differences
between
68Ga and
89Zr were seen in liver and kidney, and at
1 h p.i. a significant difference was also observed for spleen
(p<0.001).
PET study
To exclude possible radioactivity uptake in non-evaluated
tissues in the biodistribution studies a PET imaging study
was performed. In Fig. 4 representative PET images are
shown; a static PET image obtained 2–3 h after injection of
68Ga-Df-Bz-NCS-7D12 is seen in the left image while the
right image represents a mouse 2–3 h after injection of
89Zr-Df-Bz-NCS-Df. In both images the tumours are clearly
visible, with good tumour to background contrast. High
accumulation in the kidney and bladder was observed.
Discussion
In this study, we describe a method for labelling of αEFGR
Nanobody 7D12 with
68Ga using the novel bifunctional
desferal chelate (Df-Bz-NCS) which was previously intro-
duced for the coupling of
89Zr to intact mAbs [22, 23].
Using this method, stable
68Ga-7D12 radioimmunoconju-
gates were produced as demonstrated by stability testing in
storage buffer as well as in human serum with only slightly
less stability as compared with the reference compound
89Zr-Df-Bz-NCS-7D12. In addition, high and selective
tumour uptake was observed in biodistribution and PET
imaging experiments in nude mice bearing A431 xeno-
grafts, which was similar for
68Ga-7D12 and the reference
conjugate
89Zr-7D12. The latter indicates that Df-Bz-NCS
is equally well suited for immuno-PET imaging, irrespec-
tive of whether the short-lived positron emitter
68Ga or the
long-lived positron emitter
89Zr is used.
89Zr-Df antibodies
have been extensively evaluated in clinical immuno-PET
studies [33].
Crucial in the labelling procedures described herein are
(1) the use of ultra pure HCl, to keep the
natGa concen-
trations as low as possible and also to minimize the
amounts of Al, Fe and Zr, being strong competitors for
complexation with Df, (2) the purification and concentra-
tion of
68Ga by use of an anion exchange column, to further
minimize the amounts of Al, Fe and Zr, to get rid of
contaminating metals originating from the generator and to
Fig. 3 Biodistribution of 7D12 labelled with
68Ga (black bars)o r
89Zr (grey bars) in A431 tumour-bearing nude mice at 1 h (a), 2 h (b)
and 3 h (c) p.i. Significant differences in uptake are marked with an
asterisk. Data are presented as average of four mice and standard
deviation
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68GaCl4
−] volumes for labelling small [16, 34], (3)
the addition of a highly concentrated NH4OAc solution to
the [
68GaCl4
−] solution for efficient radiolabelling and
stable complex formation (avoidance of the formation of
gallium-oxo-chloro intermediates), (4) the use of a com-
mercially available desferrioxamine B chelate that has been
applied safely in the clinical setting for many years [23], (5)
radiolabelling at room temperature within a relatively wide
pH range of 5.0–6.5 and (6) the use of 0.25 M NaOAc with
5m gm l
−1 gentisic acid, pH 5.5 for protection during
storage of the purified
68Ga-labelled conjugate. These
procedures appeared efficient and mild, thus avoiding
denaturation of protein, and resulted in optimal quality
conjugates at an overall radiochemical yield of 55–70%
(not corrected for decay). Therefore, these generic proce-
dures seem suitable for GMP-compliant labelling, irrespec-
tive of the intrinsic stability of the biomolecule.
The only chelate that has been used for
68Ga labelling of
mAbs or mAb-like molecules for clinical purposes is
DOTA [35]. With DOTA the best labelling kinetics were
obtained in sodium acetate buffers at low pH [36].
Tolmachev et al. evaluated the
68Ga labelling kinetics of
the DOTA-containing anti-HER2 Affibody ABY-002. La-
belling at room temperature for 5 min appeared inefficient
(decay-corrected yield of less than 5%). Only after
elevation of the temperature to 60°C or 90°C did the yield
increase to ∼30 and ∼90%, respectively. The binding and
pharmacokinetic characteristics of this particular Affibody
did not become affected upon labelling, but it is open to
question whether other proteins can resist the harsh
labelling conditions of low pH and high temperature [35,
37]. The same is true for microwave heating that has been
used for labelling of DOTA bioconjugates with
68Ga [16,
38]. In our initial studies, using DOTA-Bz-NCS, less than
60% labelling was obtained after 20 min at 45°C, while the
thus obtained labelled product was unstable. We postulate
that at lower temperature no full N-coordination occurs.
This means that the
68Ga atom becomes ligated to the
carboxyl functions of the DOTA molecule with still having
water molecules in its coordination sphere instead of N, and
that only concordant heating at elevated temperatures [37,
39] creates the additional N-coordination of the DOTA
molecule leading to the
68Ga-DOTA complex that is
suitable for in vivo applications. This important aspect of
complex formation is fully analogous to what has been
shown by us for the synthesis of the
186Re-MAG3 complex
[40].
NOTA and its derivatives as well as the recently
introduced HBED-CC chelates might have advantages over
DOTA, since labelling with these chelates can be performed
at room temperature and modest pH [19–21, 41]. These
chelates, however, have not been clinically evaluated yet,
and for us this was the reason to evaluate the desferriox-
amine B derivative. Some controversy exists about the
conditional stability constant of the Ga-Df complex at
neutral pH. The in vitro stability we found corresponds well
with the earlier findings of Smith-Jones et al. [25], Fani
et al. [27] and Furukawa et al. [24], but seems to be rather
in contrast with the findings of Caraco et al. [42] and
Govindan et al. [26]. We feel that this is only an apparent
controversy because the conditions under which Caraco
et al. produced their Ga-Df complex are completely
different. We observed that a product formed at pH=7.4
indeed suffered from instability indicating that at this pH a
certain amount of weak complexes are formed containing
partly hydrolyzed Ga ions and so being only mono- or
bidentate bound to the three hydroxamate functions. With
respect to the findings of Govindan et al. [26], they already
suggested themselves that their findings are most probably
mixed up by the fact that the linkages between their mAb
and Df are intrinsically instable.
EGFR, a tyrosine kinase receptor, is highly expressed in
many epithelial cancer cells and is a prime target for detection
and therapeutic applications. Nuclear imaging techniques
have a provenadvantage over immunohistological techniques
since nuclear imaging is noninvasive and whole-body scans
Fig. 4 Static PET image of A431 tumour-bearing mice obtained 2–
3 h after injection of
68Ga-Df-Bz-NCS-7D12 (left mouse)o r
89Zr-Df-
Bz-NCS-7D12 (right mouse). Images demonstrate similar uptake of
both tracers. Tumours are indicated by arrows. Image planes have
been chosen where both tumours were visible
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moiety might have advantages over the use of intact mAbs,
since a molecular weight of only 15 kDa allows for faster
kinetics than intact mAbs in vivo. To our knowledge,
Nanobodies have never been used for immuno-PET appli-
cations. In this study,
68Ga-labelled Nanobody 7D12 showed
high and selective uptake in A431 tumours, ranging from 6.1
to 7.2%ID/g at 1–3 h p.i., which was comparable to the
reference compound
89Zr-7D12 (7.5 to 7.4%ID/g at 1–3h ) .
Significant differences in liver and kidney uptake were
observed between the
68Ga-7D12 and
89Zr-7D12 conjugates.
These differences most probably reflect the slightly lower
stability observed in the in vitro stability experiments.
Maybe metabolite analyses might provide further insight.
Huangetal.[44] and Gainkam et al. [45] studied the same
(αEGFR) Nanobody 7D12 in the same A431 xenograft
model, but labelled with
99mTc for SPECT applications.
Tumour uptake of
99mTc-7D12 was 4.9%ID/g at 1 h p.i.
(assessed by quantitative analysis of SPECT images) and
6.1%ID/g at 1.5 h p.i. (assessed by radioactivity counting of
dissected tumours). Like
68Ga-7D12,
99mTc-7D12 showed
high kidney uptake. However, uptake of
99mTc-7D12 in lung
and spleen was higher than that of
68Ga-7D12: 2.1 and 1.4%
ID/g versus 0.5 and 0.6%ID/g at 1 h p.i. Given the superior
properties of PET in comparison to SPECT for clinical
quantitative imaging, these data suggest that
68Ga-7D12 is
the more attractive Nanobody-based probe for assessment of
EGFR expression [46, 47].
68Ga-7D12 allowed high contrast imaging at relatively
early time points (1 h p.i.) in comparison with radiolabelled
conventional intact mAbs used in other preclinical imaging
studies. For example, in recent immuno-PET studies with
64Cu- and
89Zr-labelled anti-EGFR mAb cetuximab
tumours could only be clearly delineated 16–24 h p.i. [7,
9, 48]. Another interesting small molecular protein was
introduced for imaging of EGFR, namely the 8-kDa
Affibody ZEGFR:2377 [49]. PET imaging studies in A431-
bearing nude mice showed higher tumour contrast when
50 μgo f
111In-labelled ZEGFR:2377 was injected in compar-
ison to 5 μg, whereas for both doses high liver uptake was
observed. For the 50 μg
111In-ZEGFR:2377 group, tumour and
liver uptake at 4 h p.i. was 2.4 and 5.1%ID/g, respectively.
In comparison, tumour uptake of
68Ga-7D12 in the present
study was substantially higher (7.2%ID/g at 3 h p.i.), while
liver uptake was lower (2.0%ID/g at 3 h p.i.). These
interesting differences in uptake can be ascribed to differ-
ences in reactivity with murine EGFR. Both probes can
bind to human EGFR expressed in human xenografts, but
only
111In-ZEGFR:2377 can also bind to the murine EGFR in
the liver. In accordance, initial clinical imaging studies with
111In-labelled anti-EGFR mAb 225 showed high liver
uptake, requiring relatively high mAb doses for imaging
of EGFR expression [50].
The aforementioned data indicate
68Ga-7D12 Nanobody
has potential for assessment of EGFR tumour expression;
however, for clinical application thorough dose optimiza-
tion might be needed to obtain optimal imaging results. The
latter will be easier for
68Ga-labelled Nanobodies directed
against targets that show predominantly expression in the
tumour, as was recently illustrated in PET imaging studies
with
68Ga-labelled Affibody ABY-002 directed against the
HER2 receptor [35].
Conclusion
The newly developed GMP-compliant two-step procedure
for coupling desferal to a Nanobody allows efficient and
rapid preparation of
68Ga-Nanobodies for clinical use with
high labelling yields, high radiochemical purity and
preservation of immunoreactivity. The anti-EGFR
68Ga-
Df-Bz-NCS-7D12 Nanobody showed high accumulation in
A431 xenografts in nude mice in biodistribution studies as
well as in immuno-PET, which indicates that this conjugate
can be a promising fast kinetic noninvasive imaging probe
for the detection of EGFR expression in tumours.
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